USD0.000æéå€ååŒÂ  (ET)
2.66BæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
7.190å§å€
7.210é«å€
8.92Måºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
æå€±é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
2.44%売買å転ç
7.180忥çµå€
7.180å®å€
34.28M売買代é
æå€±é¡æ ªäŸ¡åçç
13.21PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-288.06%ç·è³ç£å©çç
6.75052é±é«å€
0.64åºæ¥é«æ¯ç%
-149.27MçŽå©ç
365.56Mæ ªåŒæ°
-2.84711æ ªåœããå©çïŒEPSïŒ
1.60ããŒã¿å€
-378.29%èªå·±è³æ¬å©çç
2.00052é±å®å€
0.42%æ¯ãå¹
100.00%ç²å©çç
2.66BæäŸ¡ç·é¡
10.27ãªã¹ã¯ãªã¿ãŒã³
4.36%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
ATAI Life Sciences NVã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž108äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããããŒã«ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯10.68ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããéå»1ãæã«ãããæ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯è¯å¥œã§ããã¡ã³ãã¡ã³ã¿ã«ãºãåªããŠããŸãããããã¯ãã«ã«ã¯çŸåšã®ãã¬ã³ããè£ä»ãããã®ã§ã¯ãããŸãããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
ATAI Life Sciences NVã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
ATAI Life Sciences NVã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
ATAI Life Sciences NV ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
ATAI Life Sciences NV
ATAI
15
Ionis Pharmaceuticals Inc
IONS
26
ææšî
ææš
売ã(2)
äžç«(1)
è²·ã(3)
ç§»åå¹³å
売ã(0)
äžç«(0)
è²·ã(6)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ATAI Life Sciences NVã®äŒæ¥æ
å ±î
Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
äŒæ¥ã³ãŒãATAI
äŒæ¥åATAI Life Sciences NV
æé«çµå¶è²¬ä»»è
ãCEOãRao (Srinivas G)
ãŠã§ããµã€ãhttps://www.atai.com/
æ ªäž»çµ±èšî
ãããã質å
ATAI Life Sciences NVïŒATAIïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îATAI Life Sciences NVïŒATAIïŒã®çŸåšã®æ ªäŸ¡ã¯7.18ã§ãã
ATAI Life Sciences NVã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îATAI Life Sciences NVã®ãã£ãã«ãŒã·ã³ãã«ã¯ATAIã§ãã
ATAI Life Sciences NVã®52é±é«å€ã¯ãããã§ããïŒ
îATAI Life Sciences NVã®52é±é«å€ã¯6.75ã§ãã
ATAI Life Sciences NVã®52é±å®å€ã¯ãããã§ããïŒ
îATAI Life Sciences NVã®52é±å®å€ã¯2.00ã§ãã
ATAI Life Sciences NVã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îATAI Life Sciences NVã®æäŸ¡ç·é¡ã¯2.62Bã§ãã
ATAI Life Sciences NV (ATAI) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãATAI Life Sciences NVïŒATAIïŒã®ç·åè©äŸ¡ã¯signal_holdã§ãç®æšæ ªäŸ¡ã¯10.68ã§ãã
ATAI Life Sciences NV (ATAI) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îATAI Life Sciences NVïŒATAIïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-2.91ã§ãã